Bortezomib-based induction therapy followed by intravenous busulfan–melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Gertz MA, et al. Continued improvement in survival in multiple myeloma and the impact of novel agents. Blood 2012;120(Suppl. 1): Abstract 3972.
   Google Scholar
• Lahuerta JJ, Mateos MV, Martínez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775–5782.
   PubMed Web of Science ®Google Scholar
• van de Velde H, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399–1406.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139–3146.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612–2624.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009;27:5720–5726.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621–4629.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase III study. Lancet 2010;376:2075–2085.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946–2955.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589–1596.
   PubMed Web of Science ®Google Scholar
• de la Rubia J, Roig M. Bortezomib for previously untreated multiple myeloma. Expert Rev Hematol 2011;4:381–398.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013;31:3279–3287.
   PubMed Web of Science ®Google Scholar
• Harousseau JL. Autologous transplantation for multiple myeloma. Ann Oncol 2008;19(Suppl. 7):128–133.
   PubMed Web of Science ®Google Scholar
• Ludwing H, Beksac M, Bladé J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010;15:6–25.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Harousseau JL. New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplant 2011;46:911–915.
   PubMed Web of Science ®Google Scholar
• Blanes M, de la Rubia J, Lahuerta JJ, et al. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. Leuk Lymphoma 2009;50:216–222.
   PubMed Web of Science ®Google Scholar
• Blanes M, Lahuerta JJ, González JD, et al. Intravenous busulfan plus melphalan as conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-based approach. Biol Blood Marrow Transplant 2013;9:69–74.
   Web of Science ®Google Scholar
• Carreras E, Rosiñol L, Terol MJ, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13:1448–1454.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562–1568.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Madden T, Kazerooni R, et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant 2011;17: 412–420.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013:19:1615–1624.
   PubMed Web of Science ®Google Scholar
• Talamo G, Claxton DF, Dougherty DW, et al. Bu and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant 2009;44:157–161.
   PubMed Web of Science ®Google Scholar
• Martino M, Olivieri A, Offidani M, et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs 2013;22:619–634.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martínez-López J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM200 study. Haematologica 2010;95:1913–1920.
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002;99:731–735.
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752–5758.
   PubMed Web of Science ®Google Scholar
• Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005;130:588–594.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Hassoun H, Kewalramani T, et al. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia 2006;20:345–349.
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Elder PJ, Lin TS, et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimen for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007;31:1069–1075.
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008;14:1401–1407.
   PubMed Web of Science ®Google Scholar
• Kazmi SM, Saliba RM, Donato M, et al. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 2011;46:510–515.
   PubMed Web of Science ®Google Scholar
• Rousell M, Moreau P, Hynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with the novo multiple myeloma (IFM): a phase 2 study of the Intergroupe Francophone du Myeloma. Blood 2010;15:32–37.
   Web of Science ®Google Scholar
• Huang W, Li J, Li H, et al. High-dose melphalan with bortezomib as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma 2012;53:2507–2510.
   PubMed Web of Science ®Google Scholar
• Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose and schedule finding study. Clin Cancer Res 2010;16:5079–5086.
   PubMed Web of Science ®Google Scholar
• Nishihori T, Ochoa L, Pidala J, et al. A phase II study of bortezomib plus high-dose melphalan (Mel/Vel) conditioning for autologous hematopoietic cell transplantation in multiple myeloma. Blood 2011;118 (Suppl. 1): Abstract 4158.
   Google Scholar
• Thompson PA, Prince HM, Seymour JF, et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pretreated multiple myeloma. Bone Marrow Transplant 2011;46:764–765.
   PubMed Web of Science ®Google Scholar
• Nishihori T, Alekshun TJ, Shain K, et al. Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012;157:553–563.
   PubMed Web of Science ®Google Scholar
• Wong Doo N, Thompson PA, Prince HM, et al. Bortezomib with high dose melphalan conditioning for autologous transplantation is safe and effective in patients with heavily pre-treated and high risk multiple myeloma. Leuk Lymphoma 2013;54:1465–1472.
   PubMed Web of Science ®Google Scholar